Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Recruiting · NCT06657703 · Registry updated 2025-04-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects. | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 1 | 2025-04-17 | NCT06657703 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| HC Biopharma Inc. | 9 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Peking Union Medical College Hospital | Beijing | China | 112 |
| Peking Union Medical College Hospital | Beijing | China | 62 |
| The Clinical Pharmacology Research Center of PUMCH | Beijing | China | 1 |